TF
LGND icon

Tompkins Financial’s Ligand Pharmaceuticals LGND Stock Holding History

Tompkins Financial’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-160
Closed -$17K – 430
2018
Q1 		$17K Buy
+160
New +$15.8K ﹤0.01% 333
2016
Q3 		– Sell
-56
Closed -$4K – 433
2016
Q2 		$4K Buy
+56
New +$4.16K ﹤0.01% 463

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Tompkins Financial's LGND Position: Q2 2018 in Review

Tompkins Financial sold out of Ligand Pharmaceuticals (LGND) in Q2 2018, closing a stake of 160 shares — an estimated $17K sold.

Tompkins Financial first reported a position in LGND in Q2 2016 and held it in 2 quarters. The position peaked at $17K in Q1 2018. 346 funds tracked by Wall St. Rank hold LGND as of Q2 2018.

  • Tompkins Financial reported no remaining Ligand Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Tompkins Financial sold 160 Ligand Pharmaceuticals shares in Q2 2018, an estimated $17K.
  • Tompkins Financial first reported a position in Ligand Pharmaceuticals in Q2 2016 and held it in 2 quarters.
  • Tompkins Financial's Ligand Pharmaceuticals position peaked at $17K in Q1 2018.
  • 346 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2018.

Based on Tompkins Financial's 13F filing for Q2 2018, filed 18 Jul 2018.